A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

DRUG

0.03% Bimatoprost

0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.

Trial Locations (1)

Guangzhou